Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.

ClassNone selected
MechanismNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

299 of 2118 arms with a reported figure. Choose arms to narrow the chart.

Change in body weight

Change in body weight from baseline, %

Source: Cited trial source. A line uses only weeks that source states. One week is a point, not a line from zero.

Y axis: Change in body weight from baseline, %

1009080706050403020100-10-20-30048121620243648607284Semaglutide 2.4 mg, STEP 1, week 68, -14.9%Semaglutide Semaglutide placebo, STEP 1, week 68, -2.4%Semaglutide 7.2 mg, STEP UP, week 72, -18.8%Semaglutide 2.4 mg, STEP UP, week 72, -15.5%Semaglutide Placebo, STEP UP, week 72, -3.9%Semaglutide Semaglutide, STEP 4, week 20, -8.3%Semaglutide Placebo, STEP 4, week 20, 6.5%Tirzepatide Placebo, SURMOUNT-1, week 72, -3.1%Tirzepatide 5 mg, SURMOUNT-1, week 72, -15%Tirzepatide 10 mg, SURMOUNT-1, week 72, -19.5%Tirzepatide 15 mg, SURMOUNT-1, week 72, -20.9%Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg, REDEFINE 1, week 68, -20.4%Cagrilintide/semaglutide Placebo s.c., REDEFINE 1, week 68, -3%Retatrutide 4 mg, TRIUMPH-1, week 80, -17.6%Retatrutide 9 mg, TRIUMPH-1, week 80, -23.7%Retatrutide 12 mg, TRIUMPH-1, week 80, -25%Retatrutide Placebo, TRIUMPH-1, week 80, -3.9%Survodutide 3.6 mg, SYNCHRONIZE-1, week 76, -12.2%Survodutide 6.0 mg, SYNCHRONIZE-1, week 76, -13%Survodutide Placebo, SYNCHRONIZE-1, week 76, -5.4%VK2735 2.5 mg, VENTURE, week 13, -9.1%VK2735 15 mg, VENTURE, week 13, -14.7%VK2735 Placebo 13 weeks, VENTURE, week 13, -1.7%Eloralintide Placebo, NCT06230523, week 48, -0.4%Eloralintide 1 mg, NCT06230523, week 48, -9%Eloralintide 3 mg, NCT06230523, week 48, -12%Eloralintide 6 mg, NCT06230523, week 48, -18%Eloralintide 9 mg, NCT06230523, week 48, -20%Exenatide Exenatide once weekly (EQW ), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), week 24, 3.8%Exenatide Dapagliflozin (DAPA), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), week 24, 1.5%Exenatide EQW plus DAPA, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), week 24, 6.9%Exenatide Dapagliflozin plus Glucophage (MET ER), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), week 24, 1.7%Exenatide Phentermine /Topiramate (PHEN/ TPM) ER, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), week 24, 8.1%Exenatide Exenatide once weekly extended-release, ECHO, week 36, 1.7%Exenatide Matching placebo, ECHO, week 36, 3.5%Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, week 56, 0.69%Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, week 56, 2.91%Liraglutide Liraglutide Placebo, no Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, week 56, 0.28%Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, week 56, 2.3%Liraglutide 1.8 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, week 56, 2%Liraglutide Placebo, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, week 56, -0.1%Liraglutide Metformin XR plus liraglutide, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM), week 84, -7.2%Liraglutide Metformin XR plus placebo, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM), week 84, -3.1%Liraglutide Liraglutide Pen Injector (Saxenda), SAXAPCOS, week 32, 5.7%Liraglutide Placebo liraglutide pen injector, SAXAPCOS, week 32, 1.4%Mazdutide 10 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, week 32, 96.1%Mazdutide 16 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, week 32, 92.23%Mazdutide Placebo, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, week 32, 23.97%Mazdutide 6 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, week 32, 67.64%Setmelanotide Pivotal Cohort, Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity, week 52, -5.21%Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity, week 52, -12.34%Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity, week 52, -25.83%Setmelanotide Stage 1: Setmelanotide (Open-Label), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway, week 16, -3.94%

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Semaglutide 2.4 mg, STEP 1, one timepoint
  • Semaglutide Semaglutide placebo, STEP 1, one timepoint
  • Semaglutide 7.2 mg, STEP UP, one timepoint
  • Semaglutide 2.4 mg, STEP UP, one timepoint
  • Semaglutide Placebo, STEP UP, one timepoint
  • Semaglutide Semaglutide, STEP 4, one timepoint
  • Semaglutide Placebo, STEP 4, one timepoint
  • Tirzepatide Placebo, SURMOUNT-1, one timepoint
  • Tirzepatide 5 mg, SURMOUNT-1, one timepoint
  • Tirzepatide 10 mg, SURMOUNT-1, one timepoint
  • Tirzepatide 15 mg, SURMOUNT-1, one timepoint
  • Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg, REDEFINE 1, one timepoint
  • Cagrilintide/semaglutide Placebo s.c., REDEFINE 1, one timepoint
  • Retatrutide 4 mg, TRIUMPH-1, one timepoint
  • Retatrutide 9 mg, TRIUMPH-1, one timepoint
  • Retatrutide 12 mg, TRIUMPH-1, one timepoint
  • Retatrutide Placebo, TRIUMPH-1, one timepoint
  • Survodutide 3.6 mg, SYNCHRONIZE-1, one timepoint
  • Survodutide 6.0 mg, SYNCHRONIZE-1, one timepoint
  • Survodutide Placebo, SYNCHRONIZE-1, one timepoint
  • VK2735 2.5 mg, VENTURE, one timepoint
  • VK2735 15 mg, VENTURE, one timepoint
  • VK2735 Placebo 13 weeks, VENTURE, one timepoint
  • Eloralintide Placebo, NCT06230523, one timepoint
  • Eloralintide 1 mg, NCT06230523, one timepoint
  • Eloralintide 3 mg, NCT06230523, one timepoint
  • Eloralintide 6 mg, NCT06230523, one timepoint
  • Eloralintide 9 mg, NCT06230523, one timepoint
  • Exenatide Exenatide once weekly (EQW ), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
  • Exenatide Dapagliflozin (DAPA), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
  • Exenatide EQW plus DAPA, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
  • Exenatide Dapagliflozin plus Glucophage (MET ER), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
  • Exenatide Phentermine /Topiramate (PHEN/ TPM) ER, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
  • Exenatide Exenatide once weekly extended-release, ECHO, one timepoint
  • Exenatide Matching placebo, ECHO, one timepoint
  • Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, one timepoint
  • Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, one timepoint
  • Liraglutide Liraglutide Placebo, no Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, one timepoint
  • Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, one timepoint
  • Liraglutide 1.8 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, one timepoint
  • Liraglutide Placebo, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, one timepoint
  • Liraglutide Metformin XR plus liraglutide, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM), one timepoint
  • Liraglutide Metformin XR plus placebo, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM), one timepoint
  • Liraglutide Liraglutide Pen Injector (Saxenda), SAXAPCOS, one timepoint
  • Liraglutide Placebo liraglutide pen injector, SAXAPCOS, one timepoint
  • Mazdutide 10 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
  • Mazdutide 16 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
  • Mazdutide Placebo, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
  • Mazdutide 6 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
  • Setmelanotide Pivotal Cohort, Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity, one timepoint
  • Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity, one timepoint
  • Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity, one timepoint
  • Setmelanotide Stage 1: Setmelanotide (Open-Label), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway, one timepoint

An arm with one reported week is a labeled point. It is not connected to zero.

Show as table
ArmWeekChange in body weight, %Estimand
Semaglutide 2.4 mg, STEP 168-14.9itt
Semaglutide Semaglutide placebo, STEP 168-2.4itt
Semaglutide 7.2 mg, STEP UP72-18.8itt
Semaglutide 2.4 mg, STEP UP72-15.5itt
Semaglutide Placebo, STEP UP72-3.9itt
Semaglutide Semaglutide, STEP 420-8.3efficacy
Semaglutide Placebo, STEP 4206.5efficacy
Tirzepatide Placebo, SURMOUNT-172-3.1itt
Tirzepatide 5 mg, SURMOUNT-172-15itt
Tirzepatide 10 mg, SURMOUNT-172-19.5itt
Tirzepatide 15 mg, SURMOUNT-172-20.9itt
Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg, REDEFINE 168-20.4n/r
Cagrilintide/semaglutide Placebo s.c., REDEFINE 168-3n/r
Retatrutide 4 mg, TRIUMPH-180-17.6itt
Retatrutide 9 mg, TRIUMPH-180-23.7itt
Retatrutide 12 mg, TRIUMPH-180-25itt
Retatrutide Placebo, TRIUMPH-180-3.9itt
Survodutide 3.6 mg, SYNCHRONIZE-176-12.2itt
Survodutide 6.0 mg, SYNCHRONIZE-176-13itt
Survodutide Placebo, SYNCHRONIZE-176-5.4itt
VK2735 2.5 mg, VENTURE13-9.1n/r
VK2735 15 mg, VENTURE13-14.7n/r
VK2735 Placebo 13 weeks, VENTURE13-1.7n/r
Eloralintide Placebo, NCT0623052348-0.4efficacy
Eloralintide 1 mg, NCT0623052348-9efficacy
Eloralintide 3 mg, NCT0623052348-12efficacy
Eloralintide 6 mg, NCT0623052348-18efficacy
Eloralintide 9 mg, NCT0623052348-20efficacy
Exenatide Exenatide once weekly (EQW ), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)243.8n/r
Exenatide Dapagliflozin (DAPA), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)241.5n/r
Exenatide EQW plus DAPA, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)246.9n/r
Exenatide Dapagliflozin plus Glucophage (MET ER), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)241.7n/r
Exenatide Phentermine /Topiramate (PHEN/ TPM) ER, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)248.1n/r
Exenatide Exenatide once weekly extended-release, ECHO361.7n/r
Exenatide Matching placebo, ECHO363.5n/r
Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes560.69n/r
Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes562.91n/r
Liraglutide Liraglutide Placebo, no Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes560.28n/r
Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes562.3n/r
Liraglutide 1.8 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes562n/r
Liraglutide Placebo, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes56-0.1n/r
Liraglutide Metformin XR plus liraglutide, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)84-7.2n/r
Liraglutide Metformin XR plus placebo, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)84-3.1n/r
Liraglutide Liraglutide Pen Injector (Saxenda), SAXAPCOS325.7n/r
Liraglutide Placebo liraglutide pen injector, SAXAPCOS321.4n/r
Mazdutide 10 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight3296.1n/r
Mazdutide 16 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight3292.23n/r
Mazdutide Placebo, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight3223.97n/r
Mazdutide 6 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight3267.64n/r
Setmelanotide Pivotal Cohort, Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity52-5.21n/r
Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity52-12.34n/r
Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity52-25.83n/r
Setmelanotide Stage 1: Setmelanotide (Open-Label), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway16-3.94n/r

Not shown

  • Semaglutide Semaglutide, SELECT: no timepoint reported
  • Semaglutide Placebo (semaglutide), SELECT: no timepoint reported
  • Semaglutide 1.0 mg, STEP 2: no timepoint reported
  • Semaglutide 2.4 mg, STEP 2: no timepoint reported
  • Semaglutide Semaglutide placebo I/II, STEP 2: endpoint not reported
  • Semaglutide 2.4 mg, STEP 4: no timepoint reported
  • Semaglutide Placebo, in trial, STEP 4: no timepoint reported
  • Semaglutide 15 mg, SURMOUNT-5: endpoint not reported
  • Semaglutide 2.4 mg, SURMOUNT-5: endpoint not reported
  • Semaglutide 2.4 mg, STEP HFpEF DM: no timepoint reported
  • Semaglutide Semaglutide placebo OW, STEP HFpEF DM: no timepoint reported
  • Semaglutide Semaglutide, STEP 3: no timepoint reported
  • Semaglutide Semaglutide placebo, STEP 3: no timepoint reported
  • Semaglutide 2.4 mg, STEP 3: no timepoint reported
  • Semaglutide Placebo, in trial, STEP 3: no timepoint reported
  • Semaglutide Insuline glargine U100 (reduced) + semaglutide, A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S: endpoint not reported
  • Semaglutide Insuline glargine U100 (titrated), A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S: endpoint not reported
  • Semaglutide Semaglutide, STEP-HFpEF: no timepoint reported
  • Semaglutide Placebo (semaglutide), STEP-HFpEF: no timepoint reported
  • Semaglutide 7.2 mg, A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight: no timepoint reported
  • Semaglutide 2.4 mg, A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight: no timepoint reported
  • Semaglutide Placebo, A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight: no timepoint reported
  • Semaglutide 2.4 mg, Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis: no timepoint reported
  • Semaglutide 2.4 mg, Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis: no timepoint reported
  • Semaglutide 2.4 mg, STEP 6: no timepoint reported
  • Semaglutide 2.4 mg, STEP 6: no timepoint reported
  • Semaglutide 1.7 mg, STEP 6: no timepoint reported
  • Semaglutide 1.7 mg, STEP 6: endpoint not reported
  • Semaglutide Semaglutide, STEP7: no timepoint reported
  • Semaglutide Placebo (semaglutide), STEP7: no timepoint reported
  • Semaglutide Semaglutide, STEP 5: no timepoint reported
  • Semaglutide Placebo, STEP 5: no timepoint reported
  • Semaglutide 2.4 mg, STEP 5: no timepoint reported
  • Semaglutide Placebo, in trial, STEP 5: no timepoint reported
  • Semaglutide Placebo, STEP12: no timepoint reported
  • Semaglutide 2.4 mg, STEP12: no timepoint reported
  • Semaglutide Semaglutide, STEP 10: no timepoint reported
  • Semaglutide Placebo (semaglutide), STEP 10: no timepoint reported
  • Semaglutide Semaglutide, A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity: no timepoint reported
  • Semaglutide Placebo, A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity: no timepoint reported
  • Semaglutide 2.4 mg, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
  • Semaglutide Placebo, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
  • Semaglutide Semaglutide, on treatment, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
  • Semaglutide Placebo, on treatment, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
  • Tirzepatide 15 mg, SURMOUNT-2: endpoint not reported
  • Tirzepatide Placebo, SURMOUNT-2: endpoint not reported
  • Tirzepatide 10 mg, SURMOUNT-2: endpoint not reported
  • Tirzepatide Tirzepatide (lead-in), SURMOUNT-4: endpoint not reported
  • Tirzepatide Tirzepatide MTD, SURMOUNT-4: endpoint not reported
  • Tirzepatide Placebo, SURMOUNT-4: endpoint not reported
  • Tirzepatide Tirzepatide, A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial: endpoint not reported
  • Tirzepatide Placebo, A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial: endpoint not reported
  • Tirzepatide Tirzepatide, SURMOUNT-3: endpoint not reported
  • Tirzepatide Placebo, SURMOUNT-3: endpoint not reported
  • Tirzepatide Tirzepatide MTD_GPI1, SURMOUNT-OSA: endpoint not reported
  • Tirzepatide Placebo_GPI1, SURMOUNT-OSA: endpoint not reported
  • Tirzepatide Tirzepatide MTD_GPI2, SURMOUNT-OSA: endpoint not reported
  • Tirzepatide Placebo_GPI2, SURMOUNT-OSA: endpoint not reported
  • Tirzepatide 15 mg, SURMOUNT-J: endpoint not reported
  • Tirzepatide Placebo, SURMOUNT-J: endpoint not reported
  • Tirzepatide 10 mg, SURMOUNT-J: endpoint not reported
  • Tirzepatide 15 mg, SURMOUNT-CN: endpoint not reported
  • Tirzepatide Placebo, SURMOUNT-CN: endpoint not reported
  • Tirzepatide 10 mg, SURMOUNT-CN: endpoint not reported
  • Orforglipron Placebo, ATTAIN-2: endpoint not reported
  • Orforglipron 6 mg, ATTAIN-2: endpoint not reported
  • Orforglipron 12 mg, ATTAIN-2: endpoint not reported
  • Orforglipron Placebo QD, ATTAIN-J: endpoint not reported
  • Orforglipron 6 mg, ATTAIN-J: endpoint not reported
  • Orforglipron 12 mg, ATTAIN-J: endpoint not reported
  • Survodutide 0.6 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
  • Survodutide Placebo group, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
  • Survodutide 2.4 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
  • Survodutide 3.6 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
  • Survodutide 4.8 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
  • Berobenatide Placebo, VESPER-1: endpoint not reported
  • Dulaglutide Dulaglutide Arm, Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients: endpoint not reported
  • Dulaglutide Placebo Arm, Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients: endpoint not reported
  • Exenatide Group A, Effect on Weight Loss of Exenatide Versus Placebo: endpoint not reported
  • Exenatide Group B, Effect on Weight Loss of Exenatide Versus Placebo: endpoint not reported
  • Exenatide Exenatide, The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects: endpoint not reported
  • Exenatide Placebo, The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects: endpoint not reported
  • Exenatide Group A, A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients: endpoint not reported
  • Exenatide Group B, A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients: endpoint not reported
  • Liraglutide Liraglutide Placebo, Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes: no timepoint reported
  • Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes: no timepoint reported
  • Liraglutide 3.0 mg, Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance: endpoint not reported
  • Liraglutide Placebo, Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance: endpoint not reported
  • Liraglutide 3.0 mg, SCALE™ Insulin: no timepoint reported
  • Liraglutide Placebo, SCALE™ Insulin: no timepoint reported
  • Liraglutide 3.0 mg, Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea: endpoint not reported
  • Liraglutide Placebo, Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea: endpoint not reported
  • Liraglutide Semaglutide, STEP 8: no timepoint reported
  • Liraglutide Liraglutide, STEP 8: no timepoint reported
  • Liraglutide Placebo (liraglutide), STEP 8: no timepoint reported
  • Liraglutide Liraglutide, SCALE™ IBT: no timepoint reported
  • Liraglutide Placebo, SCALE™ IBT: no timepoint reported
  • Liraglutide 3.0 mg, SCALE™ IBT: endpoint not reported
  • Liraglutide Placebo, in trial, SCALE™ IBT: endpoint not reported
  • Liraglutide Liraglutide, Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity: no timepoint reported
  • Liraglutide Placebo, Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity: no timepoint reported
  • Liraglutide Liraglutide, Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome: no timepoint reported
  • Liraglutide Placebo, Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome: no timepoint reported
  • Liraglutide 0.05 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
  • Liraglutide 0.1 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
  • Liraglutide 0.2 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
  • Liraglutide 0.3 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
  • Liraglutide 0.4 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
  • Liraglutide 3.0 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
  • Liraglutide Placebo + Metformin, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Liraglutide Liraglutide + Metformin, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Liraglutide 100 mcg, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Liraglutide 200 mcg, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Liraglutide 300 mcg, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Liraglutide 2.4 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 4.5 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 1.2 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 0.6 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 0.3 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 3.0 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 3.0 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
  • Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
  • Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
  • Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
  • Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
  • Liraglutide Orlistat, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
  • Lixisenatide Lixisenatide, 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years: endpoint not reported
  • Lixisenatide Sitagliptin, 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years: endpoint not reported
  • Mazdutide 3/6 Milligrams (mg) Mazdutide, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight: endpoint not reported
  • Oral Semaglutide Oral semaglutide, OASIS 1: no timepoint reported
  • Oral Semaglutide Oral semaglutide placebo, OASIS 1: no timepoint reported
  • Oral Semaglutide 25 mg, OASIS 4: no timepoint reported
  • Oral Semaglutide Oral semaglutide placebo, OASIS 4: no timepoint reported
  • Oral Semaglutide 50 mg, OASIS 2: no timepoint reported
  • Oral Semaglutide oral semaglutide placebo once daily, OASIS 2: no timepoint reported
  • TERN-601 250 mg, FALCON: endpoint not reported
  • TERN-601 500 mg, FALCON: endpoint not reported
  • TERN-601 750 mg, FALCON: endpoint not reported
  • TERN-601 Matching Placebo, FALCON: endpoint not reported
  • CT-868 CT-868 Placebo, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
  • CT-868 1.8 mg, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
  • CT-868 4.1 mg, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
  • CT-868 6.6 mg, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
  • HM15211 HM15211, A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD: endpoint not reported
  • HM15211 Placebo, A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD: endpoint not reported
  • Pramlintide Placebo-P + Placebo-M, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 360 mcg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 5.0 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 2.5 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 5.0 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 1.25 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 2.5 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 5.0 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
  • Pramlintide 1, Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin: endpoint not reported
  • Pramlintide 2, Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin: endpoint not reported
  • Pramlintide 3, Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin: endpoint not reported
  • Pramlintide Placebo, A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects: no timepoint reported
  • Pramlintide Pramlintide + Metreleptin, A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects: no timepoint reported
  • Pramlintide Pramlintide Acetate and Placebo, A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects: endpoint not reported
  • Pramlintide Lead-In Period, A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects: endpoint not reported
  • Bimagrumab 30 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Bimagrumab 30 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Bimagrumab 30 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Bimagrumab 1.0 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Bimagrumab 2.4 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Bimagrumab 1.0 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Bimagrumab 2.4 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
  • Naltrexone And Bupropion NB16, A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects: endpoint not reported
  • Naltrexone And Bupropion NB32, A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects: endpoint not reported
  • Naltrexone And Bupropion Placebo, A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects: endpoint not reported
  • Naltrexone And Bupropion NB32, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects: endpoint not reported
  • Naltrexone And Bupropion Placebo, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects: endpoint not reported
  • Naltrexone And Bupropion NB32, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program: endpoint not reported
  • Naltrexone And Bupropion Placebo, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program: endpoint not reported
  • Naltrexone And Bupropion NB32, A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Naltrexone And Bupropion Placebo, A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes: endpoint not reported
  • Naltrexone And Bupropion BWL + NB medication, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment: endpoint not reported
  • Naltrexone And Bupropion BWL + Placebo, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment: endpoint not reported
  • Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication, Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1): endpoint not reported
  • Naltrexone And Bupropion BWL + Placebo, Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1): endpoint not reported
  • Naltrexone And Bupropion NB medication, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy: endpoint not reported
  • Naltrexone And Bupropion Placebo, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy: endpoint not reported
  • Naltrexone And Bupropion Naltrexone+Bupropion Medication, Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a): endpoint not reported
  • Naltrexone And Bupropion Placebo, Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a): endpoint not reported
  • Naltrexone And Bupropion Naltrexone/Bupropion, Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders: endpoint not reported
  • Naltrexone And Bupropion Placebo, Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders: endpoint not reported
  • Orlistat Intensive Lifestyle Mod. Intervention, FIT-PLESE: endpoint not reported
  • Orlistat Standard Lifestyle Intervention, FIT-PLESE: endpoint not reported
  • Orlistat Placebo, Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases: endpoint not reported
  • Orlistat Orlistat, Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases: endpoint not reported
  • Phentermine And Topiramate VI-0521 Low, Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate VI-0521 Top, Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate Placebo, Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate VI-0521 Top, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate VI-0521 Mid, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate TPM 46, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate TPM 92, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate PHEN 7.5, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate PHEN 15, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate Placebo, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
  • Phentermine And Topiramate LSMT 12, SMART: endpoint not reported
  • Phentermine And Topiramate LSMT 24, SMART: endpoint not reported
  • Phentermine And Topiramate Phentermine & Topiramate, Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds: endpoint not reported
  • Phentermine And Topiramate Placebo Drugs, Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds: endpoint not reported
  • Phentermine And Topiramate Semaglutide, A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America: no timepoint reported
  • Phentermine And Topiramate Other anti-obesity medication, A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America: no timepoint reported
  • Setmelanotide Setmelanotide, Long Term Extension Trial of Setmelanotide: endpoint not reported
  • Setmelanotide Placebo, A Trial of Setmelanotide in Acquired Hypothalamic Obesity: endpoint not reported
  • Setmelanotide Setmelanotide, A Trial of Setmelanotide in Acquired Hypothalamic Obesity: endpoint not reported
  • Setmelanotide Setmelanotide (Double-Blind), Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: endpoint not reported
  • Setmelanotide Placebo (Double-Blind), Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: endpoint not reported
  • Setmelanotide Setmelanotide (Open-label), Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: endpoint not reported
  • Setmelanotide 2 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 2.5 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 3 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 20 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 25 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 3 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 30 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 20 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 25 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide 30 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
  • Setmelanotide Setmelanotide: PPL Group, Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity: endpoint not reported
  • Setmelanotide Setmelanotide: BBS Group, Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity: endpoint not reported
  • Setmelanotide 16p11.2 Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide AS Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide BBS Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide MC4R Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide SH2B1 Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide SMS Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide SRC1 Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
  • Setmelanotide Stage 2: Setmelanotide (Double-Blind), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: endpoint not reported
  • Setmelanotide Stage 2: Placebo (Double-Blind), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: endpoint not reported
  • Setmelanotide Placebo, Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients: endpoint not reported
  • Setmelanotide Setmelanotide, Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants: no timepoint reported
  • Setmelanotide Placebo, Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants: no timepoint reported
  • Setmelanotide 0.5 mg, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: endpoint not reported
  • Setmelanotide 1.5 mg, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: no timepoint reported
  • Setmelanotide 2.5 mg, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: no timepoint reported
  • Setmelanotide Placebo, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: endpoint not reported
  • Sibutramine Sibutramine, SCOUT: endpoint not reported
  • Sibutramine Placebo, SCOUT: endpoint not reported
  • Tesofensine placebo arm, 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO): endpoint not reported

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.